Informations:
Erreur:
ID
14020
Description
A Phase 2 Trial to Evaluate the Efficacy and Safety of OCV-501 in Elderly Patients With Acute Myeloid Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT01961882
Lien
https://clinicaltrials.gov/show/NCT01961882
Mots-clés
Versions (1)
- 22/03/2016 22/03/2016 -
Téléchargé le
22 mars 2016
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Eligibility Acute Myeloid Leukemia NCT01961882
Eligibility Acute Myeloid Leukemia NCT01961882
- StudyEvent: Eligibility
Similar models
Eligibility Acute Myeloid Leukemia NCT01961882
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Acute myeloid leukemia in remission
Item
Patients with aml who achieved first complete remission within one or two courses of standard induction therapy, and completed standard consolidation therapy (more than one course).
boolean
C0153886 (UMLS CUI [1])
Age
Item
Patients who are 60 years or older.
boolean
C0153886 (UMLS CUI [1])
Informed Consent
Item
Patients who have provided written informed consent within 90 days from the last dose of consolidation therapy on an informed consent form that has been approved by an institutional review board or independent ethics committee.
boolean
C0021430 (UMLS CUI [1])
Acute Promyelocytic Leukemia
Item
Patients who have acute promyelocytic leukemia (apl) with t(15;17) (q22;q12), (pml/rara) karyotype abnormalities, and other variant types.
boolean
C0023487 (UMLS CUI [1])
Peripheral Stem Cell Transplantation
Item
Patients who are scheduled for hematopoietic stem cell transplantation
boolean
C0242602 (UMLS CUI [1])
Drugs potentially affecting the immune system
Item
Patients who have received drugs potentially affecting the immune system within 4 weeks before starting imp administration or who may receive such drugs after start of the trial.
boolean
C1532237 (UMLS CUI [1])
Concurrent disease or psychiatric illness
Item
Patients who have a severe concurrent disease or psychiatric illness likely to interfere with participation in this trial.
boolean
C0205420 (UMLS CUI [1])
C0004936 (UMLS CUI [2])
C0525058 (UMLS CUI [3])
C0004936 (UMLS CUI [2])
C0525058 (UMLS CUI [3])
HIV positive
Item
Patients who are hiv antibody positive, hbv-dna positive or have unrecovered chronic hepatitis c with positive hcv antibody.
boolean
C0019699 (UMLS CUI [1])
C1168040 (UMLS CUI [2])
C1168040 (UMLS CUI [2])
cirrhosis
Item
Patients who have cirrhosis.
boolean
C0023890 (UMLS CUI [1])
Ineligibility
Item
Patients judged to be ineligible by the investigator (or subinvestigator) for any other reasons.
boolean
C1512714 (UMLS CUI [1])